CareDx (CDNA) Scheduled to Post Earnings on Wednesday

CareDx (NASDAQ:CDNA) will post its quarterly earnings results after the market closes on Wednesday, July 31st. Analysts expect CareDx to post earnings of ($0.13) per share for the quarter. CareDx has set its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, May 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.18. The company had revenue of $72.05 million for the quarter, compared to analyst estimates of $63.63 million. CareDx had a negative return on equity of 55.08% and a negative net margin of 66.59%. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CareDx Stock Down 1.5 %

Shares of NASDAQ CDNA opened at $18.72 on Tuesday. The firm has a market cap of $974.94 million, a price-to-earnings ratio of -5.47 and a beta of 1.78. CareDx has a 52-week low of $4.80 and a 52-week high of $19.58. The business’s 50 day moving average is $15.55 and its two-hundred day moving average is $11.92.

Analysts Set New Price Targets

CDNA has been the topic of a number of research analyst reports. StockNews.com lowered CareDx from a “buy” rating to a “hold” rating in a research report on Friday, July 5th. The Goldman Sachs Group upped their price objective on CareDx from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. Craig Hallum upped their price objective on CareDx from $15.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. Raymond James lowered CareDx from an “outperform” rating to a “market perform” rating in a research report on Monday, May 13th. Finally, Stephens upped their price objective on CareDx from $15.00 to $18.00 and gave the stock an “overweight” rating in a research report on Monday, May 13th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.